PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-1419

@NzTrader (Won't let me use reply for some reason)

We need more of this:


Commercial opportunities

There is a potentially large commercial opportunity for MPL in canine cancer.

The drug is already approved for veterinary use for a different indication in food-chain animals, and PharmAust is now looking to repurpose MPL as a safe and effective cancer treatment without the associated side effects of chemotherapy.

Principal Investigator, Dr Kim Agnew stated, “I have talked to a number of large pharma companies about the opportunities for monepantel, and the feeling I jget is that these pharma companies support the middle ground that monepantel provides, between that of prednisolone and chemotherapy.”

PharmAust is currently in confidential exploratory discussions with a leading global pharmaceutical company to co-develop and commercialise MPL for the treatment of veterinary cancers.

Typically, a licensing deal involves an upfront cash payment, plus remuneration of costs spent on developing the drug which would now be around $20m—$25m, as well as a 10-12% royalty on all sales of the drug.

Such a deal would mark a significant commercial outcome for PharmAust, and see it more than fully funded for all foreseeable future clinical trials.

Dialogue is continuing, and the company will also seek input from these potential licensing partners in preparation for the Phase 3 registration trial.

“The commercial target is to develop and partner a product that supersedes the current standard of care (prednisolone),” said Dr. Agnew.